{
  "trial_id": "NCT02855944",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, histological subtype, number of prior chemotherapy regimens, BRCA mutation status, disease progression status, presence of evaluable disease, availability of archival tumor tissue, prior cancer history, prior PARP inhibitor treatment, central nervous system metastases status, gastrointestinal disorder status, pregnancy or breastfeeding status, recent hospitalization for bowel obstruction.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Number of Prior Chemotherapy Regimens",
          "number of prior chemotherapy regimens"
        ],
        [
          "Combined Local and Central Lab BRCA Mutation Results",
          "BRCA mutation status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "ECOG at Baseline",
        "Number of Prior Platinum Regimens",
        "Randomization Stratification: Platinum Status",
        "Mutation Type",
        "Patients with a BRCA Reversion Mutation"
      ],
      "remaining_candidate_features": [
        "histological subtype",
        "disease progression status",
        "presence of evaluable disease",
        "availability of archival tumor tissue",
        "prior cancer history",
        "prior PARP inhibitor treatment",
        "central nervous system metastases status",
        "gastrointestinal disorder status",
        "pregnancy or breastfeeding status",
        "recent hospitalization for bowel obstruction."
      ]
    },
    "processed-gen-response": "Age, gender, histological subtype, number of prior chemotherapy regimens, BRCA mutation status, disease progression status, presence of evaluable disease, availability of archival tumor tissue, prior cancer history, prior PARP inhibitor treatment, central nervous system metastases status, gastrointestinal disorder status, pregnancy or breastfeeding status, recent hospitalization for bowel obstruction."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, Histological subtype, Number of prior chemotherapy regimens, BRCA mutation status, Baseline tumor size, Performance status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Number of Prior Chemotherapy Regimens",
          "Number of prior chemotherapy regimens"
        ],
        [
          "Combined Local and Central Lab BRCA Mutation Results",
          "BRCA mutation status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "ECOG at Baseline",
        "Number of Prior Platinum Regimens",
        "Randomization Stratification: Platinum Status",
        "Mutation Type",
        "Patients with a BRCA Reversion Mutation"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Histological subtype",
        "Baseline tumor size",
        "Performance status"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Race/Ethnicity, Region of Enrollment, Histological subtype, Number of prior chemotherapy regimens, BRCA mutation status, Baseline tumor size, Performance status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Histology, Prior Chemotherapy Regimens, Time from Last Chemotherapy, Best Response to Last Chemotherapy, CA-125 Level, BRCA Mutation Status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "ECOG at Baseline",
          "Eastern Cooperative Oncology Group (ECOG) Performance Status"
        ],
        [
          "Number of Prior Chemotherapy Regimens",
          "Prior Chemotherapy Regimens"
        ],
        [
          "Combined Local and Central Lab BRCA Mutation Results",
          "BRCA Mutation Status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "Number of Prior Platinum Regimens",
        "Randomization Stratification: Platinum Status",
        "Mutation Type",
        "Patients with a BRCA Reversion Mutation"
      ],
      "remaining_candidate_features": [
        "Histology",
        "Time from Last Chemotherapy",
        "Best Response to Last Chemotherapy",
        "CA-125 Level"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Histology, Prior Chemotherapy Regimens, Time from Last Chemotherapy, Best Response to Last Chemotherapy, CA-125 Level, BRCA Mutation Status"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, histological diagnosis, tumor grade, number of prior chemotherapy regimens, time since last chemotherapy, presence of biopsiable and evaluable disease, BRCA1/2 mutation status, performance status, body mass index (BMI), presence of central nervous system metastases, presence of gastrointestinal disorders, prior cancer history, menopausal status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Number of Prior Chemotherapy Regimens",
          "number of prior chemotherapy regimens"
        ],
        [
          "Combined Local and Central Lab BRCA Mutation Results",
          "BRCA1/2 mutation status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "ECOG at Baseline",
        "Number of Prior Platinum Regimens",
        "Randomization Stratification: Platinum Status",
        "Mutation Type",
        "Patients with a BRCA Reversion Mutation"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "histological diagnosis",
        "tumor grade",
        "time since last chemotherapy",
        "presence of biopsiable and evaluable disease",
        "performance status",
        "body mass index (BMI)",
        "presence of central nervous system metastases",
        "presence of gastrointestinal disorders",
        "prior cancer history",
        "menopausal status."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, histological diagnosis, tumor grade, number of prior chemotherapy regimens, time since last chemotherapy, presence of biopsiable and evaluable disease, BRCA1/2 mutation status, performance status, body mass index (BMI), presence of central nervous system metastases, presence of gastrointestinal disorders, prior cancer history, menopausal status."
  }
}